Brain Tumor Drugs Market by Therapy Type (Chemotherapy, Immunotherapy and Targeted therapy), by Indication (Glioblastoma, Meningioma and Pituitary Adenoma), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy and Online Pharmacy) - Global Outlook & Forecast 2022-2030
- Category: Healthcare
- Published Date: Sep 2022
- Publisher: Growth Plus Reports
- Pages: 111
The Brain Tumor Drugs Market is predicted to reach US$ by 2030 from US$ 3.24 billion in 2021, and to grow at a CAGR of 9.4% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Therapy Type (Chemotherapy, Immunotherapy and Targeted therapy), by Indication (Glioblastoma, Meningioma and Pituitary Adenoma), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy and Online Pharmacy)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd., Y-mAbs Therapeutics, Inc., Shimadzu Corporation, Bristol-Myers Squibb Company, Bayer AG, and Dr. Reddy’s Laboratories Ltd. among others
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Therapy Type (Chemotherapy, Immunotherapy and Targeted therapy), by Indication (Glioblastoma, Meningioma and Pituitary Adenoma), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy and Online Pharmacy)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd., Y-mAbs Therapeutics, Inc., Shimadzu Corporation, Bristol-Myers Squibb Company, Bayer AG, and Dr. Reddy’s Laboratories Ltd. among others
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years – 2020
2. Base Year – 2021
3. Forecasted Years – 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Brain Tumor Drugs - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Brain Tumor Drugs - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Brain Tumor Drugs - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Brain Tumor Drugs - ANALYSIS & FORECAST, BY REGION
North America Brain Tumor Drugs
1. North America Brain Tumor Drugs , by Country
1. US
2. Canada
1. North America Brain Tumor Drugs , by Product
2. North America Brain Tumor Drugs , by Type
3. North America Brain Tumor Drugs , by Gender
4. North America Brain Tumor Drugs , by Sales Channel
3. Europe Brain Tumor Drugs
1. Europe Brain Tumor Drugs , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Brain Tumor Drugs , by Product
3. Europe Brain Tumor Drugs , by Type
4. Europe Brain Tumor Drugs , by Gender
5. Europe Brain Tumor Drugs , by Sales Channel
4. Asia Pacific Brain Tumor Drugs
1. Asia Pacific Brain Tumor Drugs , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Brain Tumor Drugs , by product
3. Asia Pacific Brain Tumor Drugs , by Type
4. Asia Pacific Brain Tumor Drugs , by Gender
5. Asia Pacific Brain Tumor Drugs , by Sales Channel
5. Rest of the World Brain Tumor Drugs
1. Rest of the World Brain Tumor Drugs , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Brain Tumor Drugs , by Product
3. Rest of the World Brain Tumor Drugs , by Type
4. Rest of the World Brain Tumor Drugs , by Gender
5. Rest of the World Brain Tumor Drugs , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 59
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years – 2020
2. Base Year – 2021
3. Forecasted Years – 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Brain Tumor Drugs - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Brain Tumor Drugs - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Brain Tumor Drugs - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Brain Tumor Drugs - ANALYSIS & FORECAST, BY REGION
North America Brain Tumor Drugs
1. North America Brain Tumor Drugs , by Country
1. US
2. Canada
1. North America Brain Tumor Drugs , by Product
2. North America Brain Tumor Drugs , by Type
3. North America Brain Tumor Drugs , by Gender
4. North America Brain Tumor Drugs , by Sales Channel
3. Europe Brain Tumor Drugs
1. Europe Brain Tumor Drugs , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Brain Tumor Drugs , by Product
3. Europe Brain Tumor Drugs , by Type
4. Europe Brain Tumor Drugs , by Gender
5. Europe Brain Tumor Drugs , by Sales Channel
4. Asia Pacific Brain Tumor Drugs
1. Asia Pacific Brain Tumor Drugs , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Brain Tumor Drugs , by product
3. Asia Pacific Brain Tumor Drugs , by Type
4. Asia Pacific Brain Tumor Drugs , by Gender
5. Asia Pacific Brain Tumor Drugs , by Sales Channel
5. Rest of the World Brain Tumor Drugs
1. Rest of the World Brain Tumor Drugs , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Brain Tumor Drugs , by Product
3. Rest of the World Brain Tumor Drugs , by Type
4. Rest of the World Brain Tumor Drugs , by Gender
5. Rest of the World Brain Tumor Drugs , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 59
no record found